Related Experiment Video

Updated: Aug 19, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Tumor therapeutics by design: targeting and activation of death receptors

Harald Wajant1, Jeannette Gerspach, Klaus Pfizenmaier

  • 1Department of Internal Molecular Medicine, Medical Polyclinic, University of Wuerzburg, Germany.

Cytokine & Growth Factor Reviews
|March 1, 2005
PubMed

Insights

Death receptor ligands like TNF, CD95L, and TRAIL show cancer therapeutic potential. Novel strategies like gene therapy and fusion proteins enhance tumor targeting and reduce side effects for improved cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Death receptor ligands, including Tumor Necrosis Factor (TNF), CD95 Ligand (CD95L), and TNF-Related Apoptosis-Inducing Ligand (TRAIL), possess potent apoptosis-inducing capabilities, making them promising candidates for cancer therapeutics.
  • Clinical application of TNF is limited to loco-regional use, and data for CD95L and TRAIL are pending, highlighting challenges in achieving specific delivery and restricted action for pleiotropic cytokines.
  • Past experiences with TNF underscore the critical need for targeted delivery and controlled action to overcome limitations in developing effective cancer therapeutics from multifunctional cytokines.

Purpose of the Study:

  • To review the therapeutic potential of TNF, CD95L, and TRAIL as cancer treatments.
  • To explore advancements in enhancing the efficacy of these death receptor ligands through tumor targeting, gene therapy, and genetic engineering.
  • To assess the progress in developing novel cytokine variants and strategies to increase anti-tumoral activity while minimizing systemic side effects.

Main Methods:

  • Review of existing literature and clinical data on TNF, CD95L, and TRAIL in cancer therapy.
  • Analysis of gene-therapeutic approaches and novel cytokine variants developed over the past decade.
  • Evaluation of results from newly designed fusion proteins incorporating tumor-targeting strategies.

Main Results:

  • Gene therapy and novel cytokine variants have been developed to improve anti-tumoral activity and reduce systemic side effects.
  • Newly designed fusion proteins demonstrate enhanced tumor-directed activity.
  • Strategies involving tumor targeting and genetic engineering show promise in preventing undesirable actions of death receptor ligands.

Conclusions:

  • Targeted delivery and restricted action remain key challenges in developing death receptor ligands as effective cancer therapeutics.
  • Advancements in gene therapy, genetic engineering, and fusion protein design offer promising avenues to enhance the therapeutic window for TNF, CD95L, and TRAIL.
  • Engineered fusion proteins suggest the possibility of achieving enhanced tumor-directed activity and mitigating adverse effects, thereby broadening the therapeutic applicability of these death receptor ligands in cancer treatment.

More Related Videos

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...